Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02324439 · ClinicalTrials.gov registry record · Phase 1
Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission
A Phase 1 study, sponsored by Southern Illinois University.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02324439: Completed Phase 1 study, sponsored by Southern Illinois University.
NCT02324439 is a Phase 1 study that has completed, run by Southern Illinois University. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02324439, a Phase 1 study, has completed, sponsored by Southern Illinois University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a phase 0/phase I feasibility trial to test the hypothesis that flaxseed supplementation is an effective maintenance therapy for patients with ovarian cancer who are in clinical remission following platinum-based regimens. The investigators further hypothesize levels of estrogen metabolites and prostaglandin E2 in this patient population will correlate with recurrence of disease, extent of tumor burden, invasion and metastasis.
Primary Outcome
To determine the feasibility of administering a 20 gram (g) per day dose of ground flaxseed to patients with histology-proven epithelial ovarian cancer who have undergone surgical debulking and adjuvant chemotherapy with platinum-based regimens and are currently in clinical remission.
Interventions
- DRUG Omega Nutrition cold-milled flaxseeds
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-03 |
| Est. Completion | 2021-03 |
| Phase | Phase 1 |
What the finished NCT02324439 record still lists
NCT02324439 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 1 intervention - of which Omega Nutrition cold-milled flaxseeds is the first listed.
NCT02324439 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02324439 about?
NCT02324439 is a clinical study titled "Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission". This is a phase 0/phase I feasibility trial to test the hypothesis that flaxseed supplementation is an effective maintenance therapy for patients with ovarian cancer who are in clinical remission following platinum-based regimens. The investigators further hypothesize levels of estrogen metabolites ...
What is the current status of trial NCT02324439?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2015-03. Estimated completion is 2021-03.
What interventions are being tested in trial NCT02324439?
The interventions under investigation include: Omega Nutrition cold-milled flaxseeds (DRUG).
Who is sponsoring clinical trial NCT02324439?
This trial is sponsored by Southern Illinois University, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02324439's enrollment target sits among peer trials
15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia